Roluperidone (original) (raw)
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist under development by for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. Pre-clinical findings provide evidence of the effect of roluperidone on Brain-Derived Neurotrophic Factor (“BDNF”), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning and memory. As of May 2018, the drug was in phase III clinical trials. In May 2020, the shares of Minerva Neurosciences plummeted 67% after the trial "failed to meet its primary endpoint of reduction in negative symptoms, and key secondary endpoints of improvement in personal and social performance measurements." However, in August of 202
| Property | Value |
|---|---|
| dbo:abstract | Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist under development by for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. Pre-clinical findings provide evidence of the effect of roluperidone on Brain-Derived Neurotrophic Factor (“BDNF”), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning and memory. As of May 2018, the drug was in phase III clinical trials. In May 2020, the shares of Minerva Neurosciences plummeted 67% after the trial "failed to meet its primary endpoint of reduction in negative symptoms, and key secondary endpoints of improvement in personal and social performance measurements." However, in August of 2022 Minerva submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for the approval of roluperidone for the treatment of schizophrenia. The NDA submission in 2022 followed successful completion of a phase III clinical trial which was published in early 2022. Minerva believed that the findings of this second trial supported the claim that the drug was an effective agent for the treatment of negative symptoms in schizophrenia. However, in October 2022, FDA sent Minerva a refusal to file letter pertaining to the New Drug Application for roluperidone for treating negative symptoms in schizophrenia patients. (en) |
| dbo:casNumber | 359625-79-9 |
| dbo:drugbank | DB13080 |
| dbo:fdaUniiCode | 4P31I0M3BF |
| dbo:kegg | D11258 |
| dbo:pubchem | 9799284 |
| dbo:thumbnail | wiki-commons:Special:FilePath/MIN-101.svg?width=300 |
| dbo:wikiPageID | 48830910 (xsd:integer) |
| dbo:wikiPageLength | 6366 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1117234080 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Pruvanserin dbr:Schizophrenia dbr:MIN-117 dbr:Metabolite dbr:Risperidone dbr:Volinanserin dbr:List_of_investigational_antipsychotics dbc:Ketones dbc:Organofluorides dbc:Piperidines dbr:Oral_administration dbr:Glemanserin dbr:Lenperone dbr:Lidanserin dbr:Clinical_trial dbr:Receptor_antagonist dbr:5-HT2A_receptor dbc:5-HT2A_antagonists dbc:Antipsychotics dbc:Isoindoles dbr:Food_and_Drug_Administration dbr:Paliperidone dbr:Histamine_H1_receptor dbr:MIN-202 dbr:Affinity_(pharmacology) dbc:Sigma_antagonists dbr:Iloperidone dbr:Phases_of_clinical_research dbr:Sigma-2_receptor dbr:1-[2-(4-Fluorophenyl)-2-oxoet...in-4-yl]methyl]-3''H''-isoindol-1-one dbr:Minerva_Neurosciences |
| dbp:c | 22 (xsd:integer) |
| dbp:casNumber | 359625 (xsd:integer) |
| dbp:chemspiderid | 7975049 (xsd:integer) |
| dbp:drugbank | DB13080 (en) |
| dbp:f | 2 (xsd:integer) |
| dbp:h | 23 (xsd:integer) |
| dbp:iupacName | 2 (xsd:integer) |
| dbp:kegg | D11258 (en) |
| dbp:n | 2 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 9799284 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | C1CNCCC4=CC=CF (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | RNRYULFRLCBRQS-UHFFFAOYSA-N (en) |
| dbp:synonyms | MIN-101; CYR-101; MT-210 (en) |
| dbp:unii | 4 (xsd:integer) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Antipsychotics dbt:Drugbox dbt:Nervous-system-drug-stub dbt:Reflist dbt:Serotonin_receptor_modulators dbt:Short_description dbt:Sigma_receptor_modulators dbt:Histamine_receptor_modulators |
| dcterms:subject | dbc:Ketones dbc:Organofluorides dbc:Piperidines dbc:5-HT2A_antagonists dbc:Antipsychotics dbc:Isoindoles dbc:Sigma_antagonists |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist under development by for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. Pre-clinical findings provide evidence of the effect of roluperidone on Brain-Derived Neurotrophic Factor (“BDNF”), which has been associated with neurogenesis, neuroplasticity, neuroprotection, synapse regulation, learning and memory. As of May 2018, the drug was in phase III clinical trials. In May 2020, the shares of Minerva Neurosciences plummeted 67% after the trial "failed to meet its primary endpoint of reduction in negative symptoms, and key secondary endpoints of improvement in personal and social performance measurements." However, in August of 202 (en) |
| rdfs:label | Roluperidone (en) |
| owl:sameAs | wikidata:Roluperidone https://global.dbpedia.org/id/2N9X1 |
| prov:wasDerivedFrom | wikipedia-en:Roluperidone?oldid=1117234080&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/MIN-101.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Roluperidone |
| is dbo:wikiPageRedirects of | dbr:MIN-101 dbr:C22H23F2N2O2 dbr:CYR-101 dbr:CYR101 dbr:CYR_101 dbr:MIN101 dbr:MIN_101 dbr:MT-210 dbr:MT210 dbr:MT_210 |
| is dbo:wikiPageWikiLink of | dbr:Pruvanserin dbr:Volinanserin dbr:List_of_investigational_antipsychotics dbr:MIN-101 dbr:Glemanserin dbr:Lenperone dbr:Lidanserin dbr:C22H23F2N2O2 dbr:CYR-101 dbr:CYR101 dbr:CYR_101 dbr:MIN101 dbr:MIN_101 dbr:MT-210 dbr:MT210 dbr:MT_210 |
| is foaf:primaryTopic of | wikipedia-en:Roluperidone |
